Related Experiment Video

Updated: Aug 5, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

MPTP and other Parkinson-inducing agents

A H Schapira1

  • 1Department of Neuroscience, Royal Free Hospital School of Medicine, London, UK.

Current Opinion in Neurology and Neurosurgery
|June 1, 1992
PubMed

Insights

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) may cause parkinsonism by targeting dopaminergic neurons. This study explores MPTP

Area of Science:

  • Neuroscience
  • Toxicology
  • Neurodegenerative Diseases

Background:

  • 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is known to induce parkinsonism.
  • Dopaminergic neurons are selectively targeted in Parkinson's disease.
  • Genetic susceptibility may play a role in Parkinson's disease etiology.

Purpose of the Study:

  • To investigate the mechanism of action of MPTP and its analogues.
  • To explore the potential role of endogenous toxins in dopaminergic neuron death.
  • To understand the pathways involved in targeting mitochondrial function.

Main Methods:

  • Review of existing literature on MPTP and Parkinson's disease.
  • Analysis of uptake and conversion pathways of neurotoxins.
  • Examination of mitochondrial function in dopaminergic neurons.

Main Results:

  • MPTP and its analogues selectively target mitochondrial function.
  • Evidence suggests endogenous toxins may contribute to dopaminergic neuron loss.
  • A hypothesis linking toxin exposure and genetic susceptibility is supported.

Conclusions:

  • MPTP's mechanism provides a model for understanding Parkinson's disease pathogenesis.
  • Endogenous toxins are potential contributors to dopaminergic neurodegeneration.
  • Further research into toxin-induced neurodegeneration is warranted.

More Related Videos

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

The 6-hydroxydopamine Rat Model of Parkinson's Disease08:10

The 6-hydroxydopamine Rat Model of Parkinson's Disease

Published on: October 27, 2021

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...